semaglutide and blindness Ozempic Vision Lawsuit WebMD - Ozempic blindness isn't

A brand-new study out of Houston Methodist was the first to look specifically at people who are obese but not diabetic, which describes most women taking these drugs for weight loss

Daniel Drucker, MD, then a postdoctoral fellow in the Habener lab, characterized the enzymatic activity of GLP-1, while Jens Juul Holst, MD, at the University of Copehagen, simulatenously discovered GLP-1 regulated insulin secretion

This heralds further possibilities for molecular fluorescent probe development in this area

The Phase 3 TRIUMPH program is generating the data the FDA requires, and if the trials read out as expected, the retatrutide FDA approval story that began with a striking Phase 2 paper in 2023 will likely have its next chapter written in 2026